ArticleBMC gastroenterology2025
Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycophenolate mofetil (MMF) is a second-line agent for steroid-refractory immune checkpoint inhibitor-induced immune-mediated hepatotoxicity (IMH). However, the clinicopathologic characteristics and the efficacy and safety of MMF for steroid-refractory IMH are not fully understood.
methodsThis retrospective study enrolled 33 patients with pathologically diagnosed IMH by liver biopsy at Kyushu University Hospital between 2017 and 2023.
resultsPrednisolone (PSL) was administered as steroid monotherapy in 13 patients who were steroid-responsive or in combination with MMF in 10 patients who were steroid-refractory. Of the 10 steroid-refractory IMH cases, 9 eventually improved, but 1 was refractory to PSL + MMF. There were no adverse events related to MMF. Pathological evaluation revealed significantly more frequent cholangitis in the steroid-refractory group than in the steroid-responsive group [70.0% vs. 27.8%, p = 0.042]. The steroid-refractory IMH cases were further categorized into the MMF responder and MMF non-responder groups, according to the decreased level of alanine aminotransferase (ALT) 1 week before and after MMF initiation. Compared with the MMF responder group, the MMF non-responder group had significantly higher number of patients with cholestatic and mixed patterns and significantly longer interval from PSL initiation to MMF initiation [29 days (range: 21-60 days) vs. 20 days (range: 10-20 days), p = 0.0048].
conclusionsThis study is the first to demonstrate that cholangitis is more prominent in steroid-refractory IMH. MMF is a safe and effective second-line treatment, and its early induction should be considered in patients with histological evidence of cholangitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.